% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Malviya:289026,
      author       = {G. Malviya and T. R. M. Lannagan and E. Johnson and A.
                      Mackintosh and R. Bielik and A. Peters and D. Soloviev and
                      G. Brown and R.-F. Jackstadt$^*$ and C. Nixon and K. Gilroy
                      and A. Campbell and O. J. Sansom and D. Y. Lewis},
      title        = {{N}oninvasive {S}tratification of {C}olon {C}ancer by
                      {M}ultiplex {PET} {I}maging.},
      journal      = {Clinical cancer research},
      volume       = {30},
      number       = {8},
      issn         = {1078-0432},
      address      = {Philadelphia, Pa. [u.a.]},
      publisher    = {AACR},
      reportid     = {DKFZ-2024-00558},
      pages        = {1518-1529},
      year         = {2024},
      note         = {DKFZ-ZMBH Alliance / 2024 Apr 15;30(8):1518-1529},
      abstract     = {The current approach for molecular subtyping of colon
                      cancer relies on gene expression profiling, which is
                      invasive and has limited ability to reveal dynamics and
                      spatial heterogeneity. Molecular imaging techniques, such as
                      PET, present a noninvasive alternative for visualizing
                      biological information from tumors. However, the factors
                      influencing PET imaging phenotype, the suitable PET
                      radiotracers for differentiating tumor subtypes, and the
                      relationship between PET phenotypes and tumor genotype or
                      gene expression-based subtyping remain unknown.In this
                      study, we conducted 126 PET scans using four different
                      metabolic PET tracers, [18F]fluorodeoxy-D-glucose
                      ([18F]FDG), O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET),
                      3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT), and
                      [11C]acetate ([11C]ACE), using a spectrum of five
                      preclinical colon cancer models with varying genetics (BMT,
                      AKPN, AK, AKPT, KPN), at three sites (subcutaneous,
                      orthograft, autochthonous) and at two tumor stages (primary
                      vs. metastatic).The results demonstrate that imaging
                      signatures are influenced by genotype, tumor environment,
                      and stage. PET imaging signatures exhibited significant
                      heterogeneity, with each cancer model displaying distinct
                      radiotracer profiles. Oncogenic Kras and Apc loss showed the
                      most distinctive imaging features, with [18F]FLT and
                      [18F]FET being particularly effective, respectively. The
                      tissue environment notably impacted [18F]FDG uptake, and in
                      a metastatic model, [18F]FET demonstrated higher uptake.By
                      examining factors contributing to PET-imaging phenotype,
                      this study establishes the feasibility of noninvasive
                      molecular stratification using multiplex radiotracer PET. It
                      lays the foundation for further exploration of PET-based
                      subtyping in human cancer, thereby facilitating noninvasive
                      molecular diagnosis.},
      cin          = {A013},
      ddc          = {610},
      cid          = {I:(DE-He78)A013-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38493804},
      doi          = {10.1158/1078-0432.CCR-23-1063},
      url          = {https://inrepo02.dkfz.de/record/289026},
}